XTR004

DRUG4 trials

Sponsors

Sinotau Pharmaceutical Group

Conditions

Coronary Artery Disease (CAD)Coronary Artery Disease(CAD)Diagnostic CertaintyMyocardial IschemiaMyocardial Perfusion ImagingStable Coronary Artery Disease

Phase 1

A Study of XTR004 Radiotracer in Healthy Volunteers

CompletedNCT05195879

Sinotau Pharmaceutical GroupCoronary Artery Disease (CAD), Myocardial Ischemia

Start: 2021-03-23End: 2021-07-30Updated: 2022-02-07

Phase 2

Evaluation of XTR004 as a Novel 18F-labeled PET MPI Tracer in Diagnosis of Known or Suspected CAD

CompletedNCT05885841

Sinotau Pharmaceutical GroupCoronary Artery Disease (CAD)

Start: 2022-02-15End: 2023-05-09Updated: 2023-06-02

Comparative Imaging of XTR004 PET and MIBI SPECT in Borderline Coronary Stenosis

TerminatedNCT07187895

Sinotau Pharmaceutical GroupDiagnostic Certainty, Myocardial Perfusion Imaging, Stable Coronary Artery Disease

Start: 2024-12-19End: 2025-03-05Updated: 2026-01-12

Phase 3

Comparison of Diagnostic Accuracy Between XTR004 PET MPI and the Composite Index of Quantitative Coronary Angiography (QCA) and Fractional Flow Reserve (FFR)

RecruitingNCT07439133

Sinotau Pharmaceutical GroupCoronary Artery Disease(CAD)

Start: 2025-11-14End: 2027-10-01Target: 395Updated: 2026-03-03